BGI Genomics obtained patent authorization for non-invasive prenatal genetic testing technology in 16 countries.
Release Date:
2025-05-29 10:18
Recently, BGI Genomics' independently developed Non-invasive Fetal Trisomy Test (NIFTY) technology was granted an invention patent by the European Patent Office, effective in 15 member states including the UK, Belgium, Spain, Slovenia, Hungary, Sweden, Turkey, Switzerland, Italy, France, Denmark, Germany, Czech Republic, Poland, and Romania. This authorization was granted by the European Patent Office, which has the most stringent review process among the five major patent offices (China, Japan, South Korea, US, Europe), and is also the first non-invasive prenatal genetic testing patent approved in Europe for mainland China. At the same time, the National Intellectual Property Administration also issued a
As of August 2014, Shenzhen BGI Clinical Laboratories (hereinafter referred to as
BGI Clinical Laboratories is a leader in the non-invasive prenatal genetic testing industry, and has been committed to independent research and development and innovation in the translational application of genomics technology. Currently, it has published more than 30 academic articles related to non-invasive prenatal genetic testing, and filed 72 related patent applications, covering over 10 countries across Asia, America, and Europe. Since its promotion, the Non-invasive Fetal Trisomy Test (NIFTY) product has partnered with over 2,000 hospitals or organizations in 52 countries, including the UK, Australia, Spain, Singapore, Israel, Czech Republic, Turkey, Thailand, and China, with nearly 400,000 samples tested (as of August 2014), and an accuracy rate exceeding 99.9%. Recently, based on the original CFDA-approved detection products for Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome), BGI Clinical Laboratories has launched three chromosomal deletion/duplication syndrome detection results online for free. This does not require additional blood collection or increased testing fees, allowing users to enjoy higher sensitivity, higher accuracy, and more comprehensive testing.
The multi-country patent authorization for Non-invasive Fetal Trisomy Test (NIFTY) technology signifies a new breakthrough in broader detection range and higher detection accuracy for non-invasive prenatal testing. BGI Clinical Laboratories will continue to commit to new technology research and development and new invention breakthroughs, making genetic testing serve the public and genetic technology benefit the public, thus leading the orderly, healthy, and rapid development of the non-invasive genetic sequencing industry.
About BGI Clinical Laboratories
Since its establishment, BGI Clinical Laboratories has been committed to applying cutting-edge multi-omics research findings to medical testing in an economical and convenient way, with the aim of significantly reducing birth defects and improving the diagnosis and treatment outcomes of major diseases such as tumors. It has developed a series of testing services based on multi-omics technologies (including proprietary core technologies such as high-throughput sequencing, high-sensitivity mass spectrometry, and diagnostic big data analysis), forming a comprehensive product portfolio that spans the entire process of life conception, birth, development, and growth. Non-invasive Fetal Trisomy Test (NIFTY) is one of its important products.
About Non-invasive Fetal Trisomy Test (NIFTY)
NIFTY involves collecting peripheral blood from pregnant women, extracting cell-free DNA, using next-generation high-throughput sequencing technology, and combining it with bioinformatics analysis to determine the risk of fetal chromosomal aneuploidies. Compared to the 0.5% risk of traditional prenatal screening amniocentesis, this testing technology has a risk rate of only one in ten thousand. As of August 2014, BGI Clinical Laboratories' non-invasive prenatal genetic testing has covered over 2,000 hospitals or organizations in 52 countries, including the UK, Australia, Spain, Singapore, Israel, Czech Republic, Turkey, Thailand, and China, with nearly 400,000 samples tested, and an accuracy rate exceeding 99.9%. This technology is suitable for pregnant women with high-risk serological screening results; pregnant women carrying
Recommended News
Product Inquiry Hotline:
Agent Franchise Inquiry:
Address:
Rooms 101, 103, 105, Building D, Jianye Building, No. 96 Xiangxing Road, Xiang'an Industrial Zone, Xiamen Torch High-tech Zone
-
WhatsApp
